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Abstract 
Background:  Ebola virus like particles (EBOV VLPs, eVLPs), are produced by expressing the viral transmembrane gly-
coprotein (GP) and structural matrix protein VP40 in mammalian cells. When expressed, these proteins self-assemble 
and bud from ‘host’ cells displaying morphology similar to infectious virions. Several studies have shown that rodents 
and non-human primates vaccinated with eVLPs are protected from lethal EBOV challenge. The mucin-like domain 
of envelope glycoprotein GP1 serves as the major target for a productive humoral immune response. Therefore GP1 
concentration is a critical quality attribute of EBOV vaccines and accurate measurement of the amount of GP1 present 
in eVLP lots is crucial to understanding variability in vaccine efficacy.
Methods: After production, eVLPs are characterized by determining total protein concentration and by western 
blotting, which only provides semi-quantitative information for GP1. Therefore, a liquid chromatography high resolu-
tion mass spectrometry (LC-HRMS) approach for accurately measuring GP1 concentration in eVLPs was developed. 
The method employs an isotope dilution strategy using four target peptides from two regions of the GP1 protein. 
Purified recombinant GP1 was generated to serve as an assay standard. GP1 quantitation in 5 eVLP lots was performed 
on an LTQ-Orbitrap Elite and the final quantitation was derived by comparing the relative response of 200 fmol AQUA 
peptide standards to the analyte response at 4 ppm.
Results: Conditions were optimized to ensure complete tryptic digestion of eVLP, however, persistent missed cleav-
ages were observed in target peptides. Additionally, N-terminal truncated forms of the GP1 protein were observed in 
all eVLP lots, making peptide selection crucial. The LC-HRMS strategy resulted in quantitation of GP1 with a lower limit 
of quantitation of 1 fmol and an average percent coefficient of variation (CV) of 7.6 %. Unlike western blot values, the 
LC-HRMS quantitation of GP1 in 5 eVLP vaccine lots exhibited a strong linear relationship (positive correlation) with 
survival (after EBOV challenge) in mice.
Conclusions: This method provides a means to rapidly determine eVLP batch quality based upon quantitation of 
antigenic GP1. By monitoring variability in GP1 content, the eVLP production process can be optimized, and the total 
amount of GP1 needed to confer protection accurately determined.
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Background
Ebola is an extremely pathogenic virus that causes hem-
orrhagic fever and can result in mortality rates of up to 
90  %. The 2014 Ebola outbreak in West Africa brought 
global attention to a disease that was once only an iso-
lated-regional problem. More than a year later and with a 
death toll greater than 10,000, there is an urgent need for 
novel therapeutic strategies including treatment and pre-
vention. Virus-like-particles (VLPs) represent a new type 
of prophylactic vaccine that has had success and is com-
mercialized in products such as Cervarix (human papil-
lomavirus) and Gardasil (human papillomavirus) [1, 2]. 
VLPs are generated by exploiting the intrinsic ability of 
structural viral proteins, frequently major proteins in the 
capsid or envelop, to spontaneously self-assemble when 
expressed in mammalian cells [3]. VLPs are therefore 
composed of a subset of viral components that mimic the 
wild-type virus structure but lack viral genetic material, 
rendering them non-infectious. Unlike recombinant pro-
tein vaccines which may elicit a weak immune response 
due to non-ideal presentation of the viral antigens to the 
immune system, VLPs are usually antigenically indistin-
guishable from infectious virus particles [4–6]. These 
properties make VLPs promising candidates for new effi-
cacious vaccines against many viral pathogens including 
filoviruses such as Ebola.
Ebola Virus (EBOV) VLPs (eVLPs) are produced by 
transfection of HEK293 cells with plasmids encoding the 
genes for viral matrix protein VP40 and envelope glyco-
protein (GP) [7–9]. The envelope GP is solely responsible 
for viral attachment, fusion, and entry of new host cells, 
and it is therefore a major target of vaccine design efforts. 
When these proteins are expressed in mammalian cells, 
they self-assemble and bud from lipid rafts resulting in 
eVLPs that contain GP, VP40, and other packaged host 
proteins [10].
Each of the seven genes which comprise the EBOV 
genome is transcribed into individual messenger RNAs 
(mRNAs) with the exception of the fourth gene, which 
encodes for GP. In virus-infected cells, several GP-spe-
cific mRNAs are synthesized due to a transcriptional 
RNA editing phenomenon. Envelope GP is not the pri-
mary product of the fourth gene but instead is generated 
through transcriptional editing, which induces the EBOV 
polymerase to add an extra adenosine into a stretch of 
seven other adenosine residues at a specific-editing site 
near the middle of the coding region [11]. The EBOV 
polymerase transcribes the unedited GP gene which con-
tains seven adenosines at the editing site most of the time 
(>80 %), and these transcripts result in the expression of 
the predominant GP gene product, secretory glycoprotein 
(sGP) [12]. The addition of 2 adenosine residues at the 
editing site (total of 9) codes for a third GP gene product 
known as second secreted GP (ssGP). Both secreted forms 
have the same amino-terminal 295 amino acids as enve-
lope GP (see Fig. 1 for sequence alignment). Editing of the 
transcript (8 adenosines), results in the continuation of 
translation for an additional 381 amino acids beyond the 
editing site resulting in production of the pre-processed 
GP polypeptide (GP0). GP0 is cleaved into a large N-ter-
minal portion (GP1) and a smaller C-terminal portion 
(GP2) in the trans-Golgi network by the subtilisin-like 
proprotein convertase, furin [13]. Mature envelope GP is 
formed by the re-joining of GP1 and GP2 through disulfide 
bonding, and the GP1,2 complex is anchored in the mem-
brane by a transmembrane domain near the C-terminus 
of GP2 [14, 15]. GP1 contains a highly glycosylated mucin-
like domain (MLD) and antibodies that recognize this 
region have been shown to be protective in mouse mod-
els of lethal Ebola virus challenge [16]. In addition, many 
neutralizing antibodies, including two that comprise part 
of a promising therapeutic cocktail [17], are directed 
against the MLD [16, 18, 19].
The GP expression vector used to produce eVLP in 
HEK293 cells encodes for a transcript containing 8 aden-
osines and thus should produce only GP1,2. Large scale 
production of eVLPs is performed by contract manufac-
turing organizations and each lot is characterized after 
production by assays that measure total protein and 
GP1 concentrations (western blotting or single antibody 
ELISA). Ongoing vaccine studies in our laboratory have 
shown that eVLPs provide protection against a lethal 
dose of EBOV in mice and non-human primates when 
administered with an appropriate adjuvant [20, 21]. Vac-
cine dosages are administered based on GP1 protein con-
centration; however, the effectiveness (based on survival) 
of each small scale VLP preparation can be highly vari-
able. Therefore improved methods are needed to serve 
as lot release assays for each eVLP preparation to ensure 
that only material of sufficient quality is used for in vivo 
evaluation.
This report describes the development of an isotope 
dilution full scan LC-HRMS method for the absolute 
quantitation of Ebola GP1 in eVLP. The protocol resulted 
in the quantitation of GP1 with a lower limit of quanti-
tation of 1fmol and an average percent coefficient of 
variation (%CV) of 7.6  %. The optimized MS quantita-
tion of GP1, in contrast to the western blot quantitation, 
correlated with survival in vaccinated mice after EBOV 
challenge. This assay provides a means to monitor eVLP 
batch variability based on GP1 content, provides informa-
tion for the optimization of production techniques, and 
will assist in the determination of the dosage needed to 
confer protection in vaccinated animals.
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Fig. 1 Target peptide selection and characterization. Top Sequence alignment of the 3 proteins (GP1, sGP and ssGP) derived from the Ebola GP 
transcript showing the locations of target peptide candidates for use in the quantification of Ebola GP1 (red dotted boxes) as well as the location of 
peptides rejected for the final assay (black boxes). All three protein products share sequence homology in the first 295 amino acids. Peptides identi-
fied in survey runs were evaluated for absence of post translational modifications, ionization efficiency and protein location. Bottom Schematic of 
fully processed GP1,2 transmembrane protein, showing the location of the receptor binding site (RBS) and mucin-like domain (MLD) of GP1, as well 
as the extracellular domain (ECD), transmembrane region (TM) and cytoplasmic tail (CT) of GP2. GP1 and GP2 are disulfide linked to form the mature 
GP1,2 complex
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Methods
Generation and characterization of eVLPs
eVLPs were produced under a contract with Paragon 
Bioservices (Baltimore, MD) using a modification of 
the procedure described by Warfield et al. [22]. In brief, 
eVLPs were created by transfecting HEK 293 cells with 
expression vectors containing the genes for envelope GP 
and VP40 proteins [7, 22–24]. To purify the eVLPs, the 
clarified cell supernatants were pelleted, separated on a 
20–60  % continuous sucrose gradient, concentrated by 
a second centrifugation, and resuspended in endotoxin-
free PBS. The gradient fractions containing the eVLPs 
were determined via western blotting using an anti-
GP1 antibody (6D8). The total protein concentration of 
each eVLP preparation was determined in the presence 
of Nonidet P-40 detergent using a detergent-compati-
ble protein assay (Bio-Rad). For these blots unpurified 
recombinant GP material was used as an assay standard 
for the generation of a standard curve and quantitative 
information (performed by the contractor).
Generation and characterization of a recombinant GP1 
standard
A batch of recombinant Ebola glycoprotein (rGP, car-
rying an N-terminal poly-histidine tag) was expressed 
in human HEK293 cells and subsequently purified by 
immobilized metal affinity chromatography (IMAC). The 
material was produced under a contract with the Fred-
erick National Laboratory for Cancer Research (Freder-
ick, MD). Analytical scale reverse phase chromatography 
was used to further fractionate the protein preparation 
under reducing conditions. Recombinant Ebola glycopro-
tein material was reduced with 2-mercaptoethanol (final 
concentration, 0.5  M) during a 30  min room tempera-
ture incubation and then injected (300 µg total protein) 
onto an apHera C4 column (150  mm ×  4.6  mm, 5  µm; 
Supelco). Mobile phases were as follows: (A) 0.1  % trif-
luoracetic acid (TFA) and (B) acetonitrile/0.1 % TFA. The 
flow rate was set to 0.5 mL/min and rGP was separated 
using the following gradient: 0–3 min: 10 % B, 3–5 min: 
10–20 % B, 5–65 min: 20–45 % B, 65–71 min: 45–80 % B, 
and 72–82 min: 80–10 % B. During the 20–45 % B gradi-
ent, nine peaks were collected and dried to completion in 
a vacuum concentrator. All GP1 purification experiments 
were conducted using an Agilent 1200 HPLC system 
equipped with a UV detector; eluents were continuously 
monitored at 214 nm.
Each fraction of purified rGP1 was re-dissolved in 
100  µL of 8  M urea/PBS. The protein concentration 
of each fraction was estimated by measuring the opti-
cal density (OD) at 280 nm in a spectrophotometer and 
assuming an extinction coefficient at 1  % equal to 10 
(under this assumption, a 1 mg/mL solution of a protein 
would have an OD reading of 1.0). Protein from each 
fraction (500 ng) and 1 µg of the original unfractionated 
GP material were resolved on a 4–12 % BOLT SDS PAGE 
gel (Life Technologies) and stained with silver (Pierce 
Silver Stain kit, Fisher Scientific) following the manufac-
turer’s instructions. Following the initial characterization 
experiment, a larger scale purification experiment was 
conducted to obtain a sufficient quantity of GP1. In this 
iteration, 300  µg of unpurified recombinant GP mate-
rial was fractionated by reverse phase HPLC and a single 
peak corresponding to GP1 was manually collected. The 
OD at 280  nm was recorded and a preliminary protein 
concentration was determined for the sample using a 
theoretical molar extinction coefficient of 54,768 (calcu-
lated from the primary sequence of GP1 using the pro-
tein parameter tool on the ExPASy server, http://web.
expasy.org/protparam/). The sample was subsequently 
aliquoted and dried under vacuum centrifugation. SDS 
PAGE was used to compare the rGP1 pool to the original 
unfractionated rGP material. For this experiment, 2.5 µg 
of rGP1 and 3.3 µg of unfractionated rGP were resolved 
on a 4–12  % BOLT SDS PAGE gel (Life Technologies) 
and stained with Coomassie Blue (Imperial protein 
stain, Fisher Scientific). Lastly, the protein content of the 
pooled and purified rGP1 preparation was determined 
by amino acid analysis (AAA) following acid catalyzed 
hydrolysis by Biosynthesis (Lewisville, TX). AAA con-
ducted on triplicate rGP1 samples determined that on 
average, each aliquot contains 1.8 µg of protein.
Western blot analysis
Based on total protein concentration, approximately 
20–50 ng of each eVLP lot was loaded onto a 4–12 % SDS 
PAGE gel and run under reducing conditions. Known 
amounts of recombinant Ebola GP material (purified GP1 
and unpurified) were also loaded on the gel. Two separate 
gels were run for the eVLP lots tested and transferred to 
PVDF membranes. Each blot was blocked overnight with 
Odyssey blocking buffer in phosphate buffered saline 
(PBS) (LI-COR Biosciences Lincoln, NE) and then incu-
bated with primary antibody against GP1 (6D8 or F88.
H3D5, 1:1000) for 1 h at room temperature. After wash-
ing 3× with PBS + 0.1 % Tween-20 for 5 min, secondary 
antibody (1:5000) goat α-mouse IRDye® 680 labelled (LI-
COR) was added and the blots were incubated an addi-
tional hour. The blots were again washed 3× with PBST, 
and then stored in PBS until visualized with an Odyssey 
infrared imaging system (LI-COR Biosciences Lincoln, 
NE: model number 9210).
Preparation of eVLP and rGP1 standard proteolytic digests
Upon receipt of each lot of eVLP from the contractor, 
stocks were divided into 10 µg aliquots based on the total 
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protein concentration and stored at −80 °C until use. For 
simplicity, each of the 5 lots of eVLP used in this study 
was designated using alphabetical values (A–E). Sample 
preparation for MS was performed by first increasing 
the volume of each aliquot to 50µL with ‘Solution tA’ 
(25 mM Tris–HCl, pH 8.0), reducing with 55 mM DTT 
at 55  °C for 30  min, and then alkylating with 68  mM 
iodoacetamide at room temperature for 45 min. Both of 
these steps were performed in the presence of 0.05 % Pro-
teaseMax™ (Promega Madison, WI). The total volume 
was then increased to 95 µL with ‘Solution tD’ (25 mM 
Tris–HCl, pH 8.0, 10 % acetonitrile) and 4 µL of a 0.1 µg/
µL sequencing grade trypsin/lys-C solution (Promega) 
and 1 µL of 1 % ProteaseMax™ were added followed by 
incubation at 42 °C for 4 h. Digests were heated to 90 °C 
for 5  min, dried completely by speed-vac and stored at 
−80  °C until analyzed. The purified rGP1 standard was 
digested using the same protocol as the eVLPs with the 
exception that the concentration of the trypsin/lys-C was 
reduced fourfold.
Quantitation of GP1 by LC‑HRMS
AQUA Ultimate™ peptides (Thermo Fisher Scientific) 
were synthesized based on the results of extensive sur-
vey runs of purified and digested rGP1 to determine 
which endogenous peptide sequences had the fewest 
possible post-translational or artefactual modifications 
and resulted in unambiguous MS2 spectra for identifi-
cation, as well as consistent and chromatographically 
distinct extracted ion chromatograms (XIC) for quantita-
tive measurement. The following four peptide sequences 
were selected: 301-IRSEELSFTAVSNR-314, 303-SEELS-
FTAVSNR-314, 65-SVGLNLEGNGVATDVPSATK-84, 
and 65-SVGLNLEGNGVATDVPSATKR-85. Each pep-
tide had a C-terminal amino acid modified with 13C and 
15N isotopes resulting in a 10 and 8 Da mass increase for 
arginine and lysine respectively. AQUA peptides were 
supplied by the manufacturer in a 5 % acetonitrile, 0.1 % 
formic acid solution at 5  pmol/µL. A 2× working solu-
tion was prepared in 40 % acetonitrile, 0.1 % formic acid 
by adding 8 µL of each stock peptide into a total volume 
of 200  µL (200  fmol/µL). The analyte digest was resus-
pended in 60 or 80  µL 40  % acetonitrile, 0.1  % formic 
and a 4-point, twofold serial dilution performed. AQUA 
peptides were then spiked into each analyte dilution at 
a 1:1 (v:v) ratio resulting in a 100 fmol/µL AQUA stand-
ard concentration. In addition, a blank was prepared by 
diluting the AQUA standards 1:1 with 40 % acetonitrile, 
0.1 % formic acid. Samples were resolved on an Acclaim 
PepMap 100 column (1  mm  ×  100  mm) packed with 
3um, 100A C18 particles and analyzed in triplicate from 
lowest to highest concentration by loading 2 µL onto an 
Ultimate 3000 HPLC (Thermo Fisher Scientific). Mobile 
phases were as follows: (A) 0.1  % formic acid (FA) and 
(B) acetonitrile/0.1 % FA. The flow rate was set to 75 µL/
min and peptides were eluted using a 17-min linear gra-
dient of 1–34 % mobile phase B. The column eluent was 
connected to an Orbitrap Elite mass spectrometer with 
a HESI-2 ion source (Thermo Fisher Scientific) using a 
sheath gas pressure of 20 psi and an auxiliary gas flow of 5 
units. The electrospray ionization voltage was 5.0 kV with 
an ion transfer tube temperature of 350 °C and S-lens RF 
at 50 %. The automatic gain control target was 5.0 × 104 
for Orbitrap in SIM mode and 1.0 ×  104 for linear ion 
trap in MS/MS mode. The maximum injection time for 
MS/MS was set to 30 ms. Four consecutive 200 amu SIM 
scans over the range of m/z 415–1215 at a resolution of 
60,000 were used to detect the ions of interest followed 
by 4 targeted MS/MS low resolution CID scans of the 
most prominent analyte peptides for sequence verifica-
tion. For each peptide (heavy and light), both the dou-
bly and triply charged ions were considered and used for 
quantitation. The average of triplicate extracted ion chro-
matogram (XIC) counts of each of the 4 standard AQUA 
peptides, the 4 analyte peptides and deamidated SVG 
peptides were obtained using XCalibur 2.0 (Thermo Sci-
entific) with automatic integration baseline window set at 
10 scans, area noise factor at 5, and peak noise factor set 
to 20. The XIC counts from each SVG, SVGR, SVGdeam, 
and SVGRdeam peptide charge state were first summed in 
each individual replicate run and then the average for the 
three technical repeats was determined to represent the 
contribution of peptide Set 2 at each dilution. The SEE 
and IRSEE (peptide Set 1) values were obtained similarly. 
The AQUA standard peptide XIC counts were then used 
to calculate the ratio of AQUA peptide standard to the 
‘light’ analyte peptide at each dilution using a mass toler-
ance of 4 ppm. This ratio or relative response was used to 
generate standard curves which were then used to deter-
mine the amount of analyte in fmols injected on-column. 
These  fmol values were then converted to µg to calcu-
late the total GP1 using a total protein mass of 50,916 Da 
(UniProt entry Q05320, 33-501).
Limit of quantitation and linearity of analyte peptides
A previously quantified digest of a eVLP lot ‘A’ was 
diluted to 140 fmol/µL GP1 in 40 % acetonitrile, 0.1 % for-
mic acid and serially diluted twofold down to 0.5 fmol/µL 
for a total of 9 dilutions. Using a 2 µL injection volume, 
each dilution was run in triplicate as described above 
and XIC area standard curves generated for each of the 
4 quantitation peptides ranging from 275 to 1.0 fmol. The 
similar procedure was carried out on the AQUA peptides 
except the dilution was carried to 0.4 fmol/µL.
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Deamidation of AQUA peptide standards
A 40  pmol aliquot of AQUA SVG peptide was resus-
pended in 200  µL 50  mM NH2HCO3 pH 8.1 and incu-
bated at 50  °C for 3  days then dried to completion by 
speed-vac. The sample was resuspended in 200 µL 40 % 
acetonitrile, 0.1  % formic acid and 2  µL was injected 
using the instrument and chromatographic conditions 
outlined above. Target masses were aligned by charge 
state and retention time and XIC values were derived as 
described above using a mass tolerance of 4 ppm.
In‑gel trypsin digestion
A 5  µg aliquot of VLP was fractionated by SDS-PAGE 
under reducing conditions onto a 4–12  % gel (BioRad) 
and the 10 highest intensity bands excised and minced 
into 1 × 1 mm plugs. Each sample was serially processed 
in 100 µL solution tA, then solution tB (25 mM Tris–HCl, 
pH 8.0, 50 % Acetonitrile), and finally 100 % Acetonitrile 
before being evaporated to dryness in a vacuum concen-
trator. Each gel slice was then reduced and alkylated by 
incubation in 55 mM DTT at 55 °C followed by incuba-
tion with 68 mM iodoacetamide for 45 min at room tem-
perature. Bands were dried to completion and 10  µL of 
a 12.5 ng/µL sequencing grade modified trypsin solution 
(Promega, Madison, WI) in solution tD was added and 
incubated at room temperature for 30 min until trypsin 
was absorbed. 70  µL solution tD was then added and 
samples incubated overnight at 37 °C. Peptides were then 
extracted 2× by incubating in 50  % Acetonitrile, 0.1  % 
formic acid and the combined digest were dried to com-
pletion in a vacuum concentrator.
Animals, vaccinations, and viral challenge
Research was conducted under an IACUC approved pro-
tocol in compliance with the Animal Welfare Act, PHS 
Policy, and other Federal statutes and regulations relat-
ing to animals and experiments involving animals. The 
facility where this research was conducted is accredited 
by the Association for Assessment and Accreditation of 
Laboratory Animal Care, and adheres to principles stated 
in the Guide for the Care and Use of Laboratory Animals, 
National Research Council, 2011. C57BL/6 mice were 
obtained from NCI Charles River. Female mice between 
8 and 12 weeks of age were vaccinated with 100 µL injec-
tions containing 10  µg of GP (as determined by west-
ern blot) via the intramuscular (IM) route, in the caudal 
thigh. Each lot of eVLP was irradiated at 1e6 rad to ensure 
sterility and contained less than 25 EU/mL endotoxin and 
less than 10 colony forming units (CFU) of bacteria per 
vaccination. VLP were diluted in sterile saline and vac-
cinations were administered two times, with 3  weeks 
between vaccinations. Viral challenge occurred 4  weeks 
after the second vaccination. A challenge dose of 1000 
pfu of mouse-adapted Ebola virus [25] was administered 
via the intraperitoneal route (IP). The survival data was 
pooled from tow studies with n = 10 mice each.
Statistical analysis (differences between lots, animal 
survival rates)
Survival studies were evaluated using Fisher’s exact test 
with multiple testing corrections performed by permu-
tation based on the number of comparison’s performed. 
The significance of the deviation from a null hypothesis 
(p value) was reported for the survival observed in ani-
mals vaccinated with each eVLP lot.
Results
Selection and evaluation of GP1 target peptides 
for quantitation by LC‑HRMS
In the development of a reproducible MS protein quanti-
tation scheme, the selection of target peptides is a crucial 
step, especially when the protein of interest is expressed 
in multiple isoforms, and is highly post-translationally 
modified. In both the infectious virions and eVLP prepa-
rations, GP1 and GP2 are proteolytically processed from 
the GP0 polypeptide and disulfide linked to form the 
mature GP1,2 transmembrane protein complex [2, 15] 
(see Fig. 1). Four peptides were initially identified as tar-
get candidates for the quantitation of GP1 primarily due 
to their ionization characteristics, lack of post-trans-
lational modifications and relative distance within the 
sequence. During initial LC-HRMS method development 
it was discovered that two of these peptides (173-GTTF
AEGVVAFLILPQAK[13C6, 15N2]-190) and (479-LGLITN
TIAGVAGLITGGR[13C6, 15N4]-497) failed to show con-
sistent linearity. The GTT peptide and LGL peptide have 
a Grand Average of Hydropathy score (GRAVY) [26] 
of 0.933 and 1.08 respectively, indicating a high level of 
hydrophobicity, which can hinder reliable quantitation. 
The remaining 2 peptides 65-SVGLNLEGNGVATDVPSA
TK[13C6, 15N2]-84 and 303-SEELSFTAVSNR[13C6, 15N4]-
314 (designated SVG and SEE, respectively) provided 
highly reproducible linear standard curves and were 
selected for use in the assay (see Figs.  1, 2a). The selec-
tion of these 2 peptides also offered a way to distinguish 
envelope GP1 from amino-terminal sequences containing 
fragments of the protein, as the SEE peptide sequence is 
found only in the full length GP1 molecule. Isotopically 
labelled AQUA Ultimate™ peptides (Thermo Scientific) 
were synthesized for each target peptide sequence. Syn-
thetic AQUA (Absolute QUAntitation) peptides are 
chemically and physically indistinguishable from their 
endogenous counterparts with respect to retention time, 
ionization efficiency, and MS/MS fragmentation except 
they are modified to include 13C and 15N isotopes that 
increase their relative mass by very precise increments 
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Fig. 2 Characterization of target peptide standards. a Standard curves for each target analyte peptide over a 9 point dilution showing linearity from 
275 fmols to 1 fmol total GP1. An aliquot of the previously quantified eVLP lot ‘A’ (200 fmols/µL SEE at 120 µL dilution) was resuspended 83 µL 40 % 
acetonitrile, 0.1 % Formic (137.5 fmols/µL) and serially diluted. A 2 µL injection utilizing the described instrument method was run in triplicate for 
each dilution. R2 values for all four peptides are well within the margin of significance for linearity. Also shown in tabular form are the %CV values 
for each triplicate XIC measurement for each peptide at each dilution. These data indicate linearity down to 1 fmol with the largest CV% (SVGR—
17.3 %) in dilution number ‘8’ of the serially diluted series. b AQUA-SVG peptide signal response for non-deamidated (circle) and deamidated (trian-
gle) peptide. AQUA-SVG peptide was deamidated by incubating 40 pmols at 50 °C/pH 8.0 for 2.5 days while a matching 40 pmol aliquot was stored 
at −20 °C. A 5-point, twofold serial dilution was performed resulting in a 250–15.6 fmol/µL concentration range for each sample. LC-HRMS was run 
in triplicate on each dilution and the average counts plotted
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[21]. For this study, AQUA Ultimate™ peptides were 
selected as they have the highest available concentration 
precision and purity.
 During the initial survey runs which were conducted 
to optimize digestion of the eVLP for completeness and 
reproducibility, it was observed that two missed cleav-
age sites appeared regularly: a C-terminal arginine on 
the SVG peptide and an N-terminal arginine on the SEE 
peptide. We rigorously searched for additional missed 
cleavages as well as non-specific cleavages upstream and 
downstream of the fully tryptic peptides, and found no 
evidence that these species were present (see Additional 
file 1: Table S1). Given that the ratio of missed cleavage 
to fully tryptic peptides was highly variable (0.4–45  %), 
the 2 peptides representing these missed cleavages 
(65-SVGLNLEGNGVATDVPSATKR[13C6, 15N4]-85 and 
301-IRSEELSFTAVSNR[13C6, 15N4]-314) were synthe-
sized and evaluated for reproducibility and linearity. 
These peptides were chromatographically distinct, gen-
erated linear standard curves and were therefore suitable 
for use in the quantitation assay (see Fig. 2a; Additional 
file 2: Figure S1). It was also observed that one of the two 
asparagine residues within the endogenous SVG pep-
tide, but not both, were routinely deamidated. Since all 
extracted-ion chromatogram (XIC) counts from this spe-
cies must be combined with the non-deaminated values 
in order to account for the full stoichiometric contribu-
tion of the SVG peptide it was evaluated whether the 
non-deamidated AQUA SVG peptide standard could be 
used to quantitate the level of deamidated analyte pep-
tide. The standard AQUA SVG and SVGR peptides were 
fully deamidated by incubating them at 55 °C for 2.5 days 
at pH 8.1, and evaluated using the developed LC-HRMS 
method. Interestingly, even with this harsh treatment, 
the doubly deamidated species comprised only 5  % 
of the total SVG peptide compliment, indicating that 
under normal processing conditions it would be a highly 
unlikely modification (see Additional file  3: Figure S2). 
The XIC response of the deamidated peptide standards 
were then compared to the non-treated peptide stand-
ard of the same concentration. As shown in Fig. 2b, the 
response was essentially identical. Therefore, the XIC 
counts derived from the SVG and SVGR standard AQUA 
peptides were used to quantify the additional XIC counts 
from the endogenous deamidated peptide species with-
out necessitating the production of additional labeled 
deamidated standards. We did not observe deamidation 
of the single asparagine in the SEE target peptide.
Determination of optimal digestion conditions for GP1 
within the eVLPs
The proteolytic enzyme of choice is a mass spectrometry 
grade Trypsin/Lys-C combination (Promega #V5073) 
as it is well characterized, versatile and highly specific. 
Initial digestion experiments and LC-HRMS analysis of 
the eVLPs revealed that some regions of GP1 are very 
resistant to proteolytic digestion even in the presence of 
enhancing surfactants such as ProteaseMax™. To ensure 
complete digestion of the eVLP GP1, we conducted 
extensive testing using a variety of buffer formulations, 
reagents, and pre-digestion treatments. These treatments 
included deglycosylation, sonication and high tempera-
ture. Since GP1,2 is a heavily glycosylated membrane 
embedded protein, we performed PNGase deglycosyla-
tion prior to digestion in the hope of reducing steric 
hindrance of the sugars and thereby enhancing trypsin 
proteolysis. Although we observed a modest improve-
ment in overall peptide count as well as a reduction in 
frequency of the SVG/SEE missed cleavages, we did not 
observe any appreciable differences in the ratios of the 
target peptides selected for use in quantitation (data not 
shown). Therefore it was concluded that the additional 
deglycosylation procedure would only add to the com-
plexity of the assay. We also tested the cleavable deter-
gent/surfactant, ProteaseMax™ (Promega, Madison, WI), 
which is designed to enhance the performance of trypsin, 
and is especially useful for membrane proteins. This rea-
gent dramatically reduced the overall number of missed 
cleavages and allowed the digest time to be reduced from 
16 to 4 h without any loss of digestion efficiency. Despite 
these efforts, we were unable to completely eliminate 
the occurrence of the target peptide missed cleavages 
described above. However, we did not observe any addi-
tional upstream or downstream missed cleavage species 
from either target peptide in survey runs from each eVLP 
lot tested (Additional file  1: Table S1). Missed cleavage 
species were observed in 8.2  % of the SEE peptide and 
31 % in the SVG peptide. These values represent the typi-
cal level observed in all 5 eVLP lots tested after trypsin 
digestion. We therefore concluded that the 4 peptides 
selected for the assay would be adequate for quantita-
tion of GP1 present in eVLP preparations. The final pep-
tide sequences and charge states used for quantitation of 
Ebola GP1 are shown in Table 1.
Reverse phase purification of GP1 standard
In any protein quantitation experiment, the assumption 
is that unique peptides from different regions within a 
protein will display a 1:1 molar relationship. However, 
early quantitation experiments with test lots of recom-
binant GP material and eVLP revealed a variable target 
peptide (SVG:SEE) stoichiometric ratio (designated as ΔS 
below) between the lots which was otherwise consistent 
within each lot. In some cases the disparity between the 
SVG quantitation and the SEE quantitation was as high 
as 25  %. In order to rule out experimental error as the 
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cause of the discrepancy, we prepared a pure monomeric 
full length rGP1 standard from recombinant GP material 
(containing GP1 and GP2) that could be used to assess 
the accuracy of the quantitation method. As shown in 
Fig.  3a, a reverse phase chromatography procedure was 
performed that fractionated reduced rGP material into 
multiple sub-species. Fractions were collected and evalu-
ated by SDS PAGE analysis and silver staining. As seen 
in Fig. 3b, fractions 1–4 and fractions 6–7 constitute GP1 
and GP2, respectively. Interestingly, fractions 1–4 yielded 
nearly identical SDS PAGE profiles despite observing 
multiple shoulder peaks on the reverse phase chromato-
gram. Ultimately however, the fractionation procedure 
resulted in a significant enrichment of individual protein 
species within the rGP preparation, and SDS PAGE anal-
ysis confirmed that the fractionated material was highly 
enriched for GP1 (see Fig. 3c). Collectively, this data indi-
cates that the procedure significantly reduced the amount 
of heterogeneity in the original sample and produced an 
enriched version of GP1 that was suitable for use as an 
assay standard.
Validation of the quantitation method with purified rGP1 
standard
Quantitative amino acid analysis (AAA) indicated each 
aliquot of purified rGP1 contained an average of 1.8  µg 
GP1 protein. In order to evaluate the accuracy and preci-
sion of the assay, four rGP1 aliquots were resuspended in 
80 µL 40 % acetonitrile with 0.1 % formic acid and quan-
titated in triplicate using the LC-HRMS assay. As seen in 
Table 2, after averaging the individual peptide set values, 
the GP1 concentration was determined to be 1.45  µg/
aliquot for trial 1 and 1.52  µg/aliquot for trial 2. These 
values are within 20.5 and 15.5  % of the value obtained 
with AAA (1.8 µg). The SVG/SEE stoichiometric dispar-
ity (designated as ΔS), was 4.6 % for trial 1 and 5.5 % for 
trial 2 and the  %CV was 3.2. These data indicate that the 
LC-HRMS method using the combination of these 4 pep-
tides (Set 1 and Set 2) was sufficient to account for the 
GP1 protein present with an average accuracy 82.5 %.
Development of a high resolution/accurate mass (HR/AM) 
quantification of GP1 in eVLPs
Since the purified rGP1 standard returned acceptable LC-
HRMS quantitation results, we sought to determine the 
source of the disparity observed in the quantitation of 
GP1 in the eVLPs when using peptide Set 1 and peptide 
Set 2 (ΔS). While the eVLPs are designed to produce only 
GP1,2 by altering the primary sequence used to transfect 
the HEK293 cells, the presence of multiple forms of GP 
was observed by western blotting using two monoclo-
nal antibodies with epitopes located in different regions 
of the molecule (see Fig. 3d, e). The mouse monoclonal 
antibody 6D8 binds at amino acids 389-405 and therefore 
has affinity for Ebola GP1 only [16]. This is the antibody 
routinely employed for the determination of GP content 
in the eVLP preparations by quantitative western blot or 
ELISA. Antibody H3D5 is a mouse monoclonal antibody 
which binds at amino acids 72-109 and therefore has 
affinity for all forms of GP (both secreted and membrane 
bound) (see Fig.  1) each containing the SVG peptide 
sequence. This antibody has reactivity with all subtypes 
of Ebola GP1, for all subspecies [27]. As shown in Fig. 3d, 
e, the predominant band visualized using both antibod-
ies in the unfractionated rGP material, purified rGP1, 
and two lots of eVLPs (lots ‘A’ and ‘E’), is fully glyco-
sylated GP1 (~ 140 kDa). However the H3D5 blot shows 
the presence of strong distinct bands of a lower molec-
ular weight (~50 to 100 kDa) present in both eVLP lots 
and the unpurified rGP material. These bands are much 
reduced in the rGP1 purified standard compared to the 
unpurified rGP material. The additional bands visible in 
the eVLP western blot using the H3D5 antibody do not 
correspond to the correct molecular weight for either 
sGP or ssGP (50 and 47  kDa respectively). In order to 
verify sequence identity these bands were excised from a 
gel of one eVLP lot (‘A’) and stained for total protein with 
coomassie blue. The 10 most intense bands were excised; 
trypsin digested, and analyzed with long-gradient CID 
survey runs as well as targeted LC-HRMS MS to iden-
tify any GP protein fragments contributing to the peptide 
quantitative variability. The results of this sequencing 
experiment are shown in Additional file 4: Figure S3. All 
bands excised were confirmed to contain EBOV GP1 or 
GP2 peptides. A gradual loss of C-terminal peptide iden-
tifications for GP1 was observed as the smaller products 
visible in the gel were sequenced, suggesting the presence 
of truncated forms of GP1 in the eVLP. This data indicates 
that peptides derived from the first ~ 200 amino acids of 
Table 1 Masses of  analyte and  AQUA standard peptides 
used for quantitation of GP1 in eVLP
Set Sequence Analyte AQUA standard
2(+) m/z 3(+) m/z 2(+) m/z 3(+) m/z
1 SEELSFTAVSNR 670.3281 447.2211 675.3322 450.5572
1 IRSEELSFTAVSNR 804.9206 536.9495 809.9248 540.2856
2 SVGLNLEGNGVATD-
VPSATK
964.9998 643.669 969.0069 646.3404
2 SVGLNLEGNGVATD-
VPSATKR
1043.0498 695.7027 1048.0549 699.0388
2 SVGLNLEGNGVATD-
VPSATK-deam
965.4918 643.997 N/A N/A
2 SVGLNLEGNGVATD-
VPSATKR-deam
1043.5424 696.0307 N/A N/A
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Fig. 3 Purification and characterization of a recombinant GP1 standard. a Representative chromatogram of preparative C4 reverse phase HPLC of 
300 µg reduced recombinant GP material indicating fraction collection points. b SDS PAGE followed by silver-staining of fractions 1–7 showing the 
separation of GP1 (top arrow) and GP2 (bottom arrow). Material from fraction 1 was divided into 1.8 µg aliquots and used for quantitation standard. c 
Silver stained SDS PAGE performed under reducing conditions comparing the rGP starting material and the purified rGP1 standard. (top arrow) GP1 
and (bottom arrow) GP2. D) Western blot of eVLP Lot ‘A’, eVLP Lot ‘E’, unpurified rGP and the purified rGP1 standard using the monoclonal antibody 
6D8 showing the detection of fully glycosylated GP1 (arrow). E) Western blot of eVLP Lot ‘A’, eVLP Lot ‘E’, unpurified rGP and the purified rGP1 stand-
ard using the monoclonal antibody H3D5 showing the detection of fully glycosylated GP1 (arrow) and GP protein fragments
Table 2 HR/AM-MS method validation using purified recombinant GP1 standard
Trial Dilution Peptide On‑column Total In  
sample (µg)
Ave. (µg) ΔS (%) Accuracy (%) Precision 
(% CV)
fmoles ng
1 80 Set 1 347.7 17.7 1.42 1.45 4.60 80.5 3.2
Set 2 363.7 18.5 1.43
2 80 Set 1 363.3 18.5 1.48 1.52 5.50 84.5
Set 2 383.4 19.5 1.56
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GP1 would not be suitable candidates for quantitation 
of the protein. We therefore concluded that the SEE tar-
get peptide (Set 1) was the only reliable standard for the 
quantitation of GP1 in eVLP.
Testing of the LC‑HRMS quantitation method 
for reproducibility with an eVLP digest
Three aliquots from a single test lot of eVLP (lot ‘A’) were 
used to evaluate the quantitation method for reproduc-
ibility. As shown in Fig. 4a, the workflow was as follows: 
heavy AQUA standard peptides were added at a fixed 
concentration of 200  fmols/injection while varying the 
concentration of the eVLP analyte digest (10  µg based 
on total protein concentration) over 4 twofold dilutions 
for a total of 5 dilutions. Each complete quantitation set 
was run in triplicate with an analyte resuspension vol-
ume of 120µL. The XIC area contributions from each 
charge state were summed to provide the total fmols for 
each peptide species (see Fig. 4b; Table 3). Replicates 1, 2, 
and 3 resulted in a calculated GP1 concentration (based 
on the SEE peptide standard set 1 only) of 0.57, 0.49 
and 0.53 mg/mL, respectively for an average of 0.53 mg/
mL ±  0.04  mg/mL and a percent CV of 7.6. Therefore, 
each aliquot of this eVLP contained an average of 1.13 µg 
of GP1, or 11.3  % of the total protein concentration of 
10 µg. The average ΔS (SVG/SEE stoichiometric dispar-
ity) value was 17.3 %. These data suggest that the newly 
developed LC-HRMS method can quantitate the amount 
of GP1 in eVLP reproducibly. 
In order to reduce the possibility of including peptide 
ion counts from contaminating ion species, our LC-
HRMS method included a second stage MS/MS step to 
fragment each of the analyte peptides to confirm target 
sequence identity. We were able to confidently identify 
each of the 4 analyte quantitation peptides in at least the 
3 highest dilutions of the test eVLP lot used to determine 
assay reproducibility. Representative MS/MS spectra of 
the SVG and SEE target analyte peptides are shown in 
Fig. 5. With the exception of the SEE peptide at the high-
est dilution, peptide assignments from every dilution 
run were of sufficient quality to obtain non-ambiguous 
sequence identifications.
Linearity and limit of quantitation of analyte peptides
To assess the lower limit of quantitation of the assay, 
and to ensure the range of protein concentrations tested 
remains linear relative to our single standard peptide 
concentration, we performed a linearity and limit of 
quantitation experiment. While the observed range of 
concentrations over 5 dilution points spanned from 6 to 
250 fmols, it was necessary to show that we could extrap-
olate to concentrations that fell outside the fixed concen-
tration represented by the AQUA peptide standards. We 
therefore prepared a dilution of a previously quantified 
eVLP lot (‘A’) such that a 9-point twofold serial dilution 
resulted in an on-column GP1 load of between 275 fmol 
and 1 fmol. The averaged triplicate XIC values were plot-
ted and %CV values determined (see Fig.  2a: tabular 
data). The quantitation remained linear across the entire 
concentration range (1–275fmol) with R2 values for 
SVG (0.9999), SVGR (0.9972), SEE (0.9986) and IRSEE 
(0.9979) well within the margin of linear significance. 
While %CV values at the highest dilutions were typically 
less than 5, the values in the 2 most dilute concentrations 
spanned a range of 7.6–17.3 %. This is within acceptable 
limits of variability and therefore the quantitative accu-
racy of the assay is reliable down to 1fmol.
Quantitation of multiple lots of eVLP and comparison 
with western blot quantitation
The optimized protocol developed for the digestion and 
LC-HRMS quantitation of GP1 was performed on digests 
of 5 different lots of eVLPs. These lots were produced 
and characterized using western blot by an outside con-
tractor (Paragon BioServices, Baltimore, MD) and, at 
the time of our study, were being used for a number of 
in-house animal vaccination studies. Using primary ali-
quots which were stored at −80 and would therefore 
experience only one freeze-thaw, eVLPs (10 ug total pro-
tein) were digested and triplicate LC-HRMS quantitation 
runs were performed. Resuspension volumes for all eVLP 
digests were 120 µL. As shown in Fig. 4b, the final quanti-
tation was derived by comparing the relative response of 
the 200 fmol AQUA standards (SEE and IRSEE: Set 1) to 
the endogenous analyte response at 4 ppm at each dilu-
tion. The average XIC’s were then calculated and used to 
obtain the final concentration of GP1 protein present in 
the eVLPs. This quantitation was performed in duplicate 
and the concentrations of GP1 for all 5 lots of eVLPs are 
shown in Table 4. The lowest percentage of GP1 relative 
to the total protein concentration was found in lot ‘E’ 
(1.2 %) with a final concentration of 0.09 mg/mL GP1. The 
next lowest values are found in the lot ‘D’ (3.0 %, 0.15 mg/
mL) while the highest percentage of GP1 relative to the 
total protein concentration was found in lot ‘A’ (11.7  %, 
0.55 mg/mL). This represents nearly an order of magni-
tude difference in relative GP1 concentration between the 
VLP lots ‘A’ and ‘E’. The ΔS values for each eVLP lot tested 
ranged from 7.35 % for the lot ‘B’ to 25.5 % for lot ‘E’.
For each eVLP lot, the GP1 concentration was deter-
mined after production by the contractor via western 
blot with the 6D8 antibody and unpurified rGP mate-
rial as a quantitation standard. As shown in Table 4, the 
range of concentration for GP1 was 0.71–1.4  mg/mL as 
determined by western blot. Total protein values pro-
vided for each lot ranged from 3.8 to 7.2 mg/mL. Since 
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the western blot quantitation and the MS quantitation 
results were vastly different we investigated the source 
of this discrepancy by repeating the western blot on the 
eVLP lots with the highest and lowest calculated GP1 
(as determined by LC-HRMS) using the 6D8 and H3D5 
antibodies (see Fig.  3d, e). As previously mentioned 
above, both eVLP lots displayed strong signals for GP1 
at ~140 kDa using the 6D8 antibody. However, the H3D5 
antibody revealed the presence of truncated products 
previously seen in the test eVLP lot and the unpurified 
rGP material. These truncated products are highly abun-
dant in the eVLP lot ‘E’, which returned the lowest con-
centration of GP1 by LC-HRMS quantitation with the 
largest ΔS value (25.5 %), whereas eVLP lot ‘A’ appears to 
have fewer detectable GP1 fragments, and returned a ΔS 
value of 15.8 %.
Correlates of VLP efficacy
In the hopes of using immune correlates as another 
measure of eVLP quality, the western blot and LC-HRMS 
quantitation results were compared to survival data in 
mice for each of these eVLP vaccine preparations. Each 
lot of eVLP was used to immunize mice (n = 20) which 
were then challenged with a murine adapted EBOV. 
For each vaccination dose, volumes of eVLP were used 
which were surmised to contain 10  µg of GP (as deter-
mined from the western blot quantitation performed by 
the contractor). As shown in Fig. 6a, lot ‘E’ exhibited the 
lowest average survival rate after Ebola challenge (40 %), 
and animals vaccinated with the lots ‘A’ and ‘B’ exhibited 
100  % survival. Lot ‘E’ contained the lowest calculated 
GP1 concentration as determined by LC-HRMS whereas 
the lot ‘A’ contained the highest. The difference in survival 
between vaccination with lots ‘A’ and ‘E’ was significant 
(p = 0.001). As shown in Fig. 6b, if we plot the percent 
survival versus the GP1 LC-HRMS quantitation in each 
eVLP lot, expressed as percent total protein, a strong pos-
itive linear correlation is observed (R2 = 0.936). A weaker 
correlation is observed if the absolute quantitation values 
for GP1 (expressed as mg/mL) obtained by LC-HRMS 
are plotted versus survival (p  =  0.9096). In contrast 
western blot quantitation values (GP1 as a percentage of 
total protein) did not display strong linear correlation 
Fig. 4 Illustration of the eVLP quantitation method workflow and cal-
culations. a VLP digests are resuspended in 120 µL and four twofold 
serial dilutions performed. Each dilution is mixed 1:1 with a solution 
containing 200 fmol/µL of each of the four isotopically labeled AQUA 
peptides and run in triplicate using 2 µL injections. b Method used 
for calculating the GP1 concentration in the rGP1 standard at each 
dilution. Average XIC area counts from the 2+ and 3+ charge states 
are first summed for each AQUA (Paq) and analyte (Pv) peptide. The 
values from the SEE and IRSEE are summed to provide the total 
counts for peptide ‘Set 1’ and the SVG and SVGR values are summed 
to provide total counts for peptide ‘Set 2’. The final quantitation is 
derived by comparing the relative response of the 200 fmol AQUA 
standard to the endogenous analyte response at 4 ppm and averag-
ing the response between the 2 peptide sets. For absolute eVLP rGP1 
quantitation, only the values derived from peptide set 1 (SEE/IRSEE) 
were used
◂
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with percent survival (R2 = 0.6904) and there was essen-
tially no correlation observed between the western blot 
GP1 concentrations (expressed as mg/mL) and survival 
(R2 = 0.0711).
The western blot quantitation of lot ‘E’ returned a value 
of 1.1  mg/mL of GP1 (see Table  4). Therefore a 10  µg 
GP1 dose would require 9.1  µL of the eVLP prepara-
tion for vaccination. However, based on the LC-HRMS 
quantitation, we can retroactively estimate that the ani-
mals were given only 0.82 µg of the 10 µg dose desired, 
which was adequate to protect only 4/10 animals vac-
cinated. Conversely, the western blot concentration 
for lot ‘A’ (1  mg/mL) is also higher than the LC-HRMS 
quantitation (0.55 mg/mL), and the 10 µL dose thought 
to contain 10 µg of GP1 actually contained 5.5 µg which 
was adequate to protect 100 % of the vaccinated animals 
after Ebola challenge. Therefore the observed differences 
in eVLP efficacy between eVLP lots ‘A’ and ‘E’ are due to 
vastly different concentrations of antigenic GP1. From 
the LC-HRMS quantitation of lot ‘B’, which also provided 
100  % survival, we can determine that a vaccine dose 
(based on the western blot quantitation) of 10  ug GP1 
would actually contain 2.89  µg which appears to be the 
minimal vaccination dose required to confer 100 % sur-
vival in mice after Ebola challenge.
Discussion
Provided that technical pitfalls such as incomplete pro-
tein extraction, incomplete proteolysis or protein side-
chain modifications are appropriately controlled and 
considered, protein quantitation by MS using an AQUA 
strategy employing stable isotope labelled peptides can 
be robust, accurate and reproducible, while achiev-
ing low limits of detection [28–30]. Ideally, target pep-
tides should be well separated on a protein of interest to 
ensure that the entire protein is sufficiently denatured 
and digested prior to quantitation. Additionally, potential 
sites of post-translational modifications or residues sus-
ceptible to artefactual modifications should be avoided. 
In reality peptide selection is an empirical process that 
balances ideal characteristics with practical limitations. 
For example, large proteins yield more potential target 
peptides than small proteins, and sequence features often 
limit the number of possible suitable target peptides. As 
we discovered with the development of a quantitation 
assay for Ebola GP1, a protein of interest may have signifi-
cant sequence homology with other protein species in a 
complex mixture, making it difficult to adhere to the pep-
tide selection criteria described above. The quantitation 
of the Ebola GP1 in eVLP preparations was a unique chal-
lenge due to the fact that during eVLP production and 
purification, truncated forms of the protein are produced 
and retained throughout the post-production processing. 
This prevented the use of target peptides located in the 
first ~200 amino acids of the GP1 sequence. Additionally 
very few suitable target peptides were available toward 
the C-terminus of the protein due to the high frequency 
of glycosylation sites and high hydrophobicity. Therefore 
we have chosen a non-traditional strategy of full scan 
LC-HRMS quantitation in which 4 target peptides rep-
resenting 2 fully tryptic and 2 missed cleavage peptides 
were employed. Previous studies have shown that the 
use of isotopically labelled target peptides with missed 
cleavages in protein quantitation results in no significant 
differences in precision, accuracy, specificity, and sensi-
tivity compared with the use of fully tryptic peptides [31]. 
In addition, to further validate the assay, a purified GP1 
standard was generated to provide quality control (for 
trypsin digestion parameters) and assay validation.
The average percent accuracy of our method based on 
quantitation of the rGP1 standard by AAA was 82.5  %. 
While the HPLC fractionation we performed resulted 
in a significant enrichment of GP1 from GP2 and trun-
cated products of GP, contaminating protein species may 
still be contributing to the final concentration based on 
AAA. Indeed, the H3D5 western blot of the purified rGP1 
revealed immune-reactive species of lower molecular 
weight, which may be the source of this overestimation, 
ultimately contributing to the apparent reduced accuracy 
of the LC-HRMS method.
The presence of truncated GP products in the eVLP 
preparations is the likely source of variation between the 
quantitation of GP1 with the two standard peptide sets. 
This hypothesis is supported by the data obtained dur-
ing the rGP1 standard assay development and testing. 
The LC-HRMS quantitation of purified rGP1 resulted in 
an average ΔS of 5.1 % as compared to the eVLP method 
validation and reproducibility trials, which showed 
Table 3 GP1 quantitation in three replicates of a single eVLP lot
Sample Digest (µg) fmoles Aliquot (µg) Concentration (mg/mL) Pct. total protein ∆S (%) CV%
Pep Set 1 Pep Set 2
Lot A (1) 10 199.1 231.1 1.22 0.57 12.2 16.1 7.60 %
Lot A (2) 10 172.3 207.1 1.05 0.49 10.5 20.2
Lot A (3) 10 183.8 212.2 1.12 0.53 11.2 15.5
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Fig. 5 Average MS/MS fragmentation spectra of the SVG and SEE peptides. Replicate CID fragmentation spectra and 300 ppm theoretical ion 
tables of the SVG (a, b) and SEE (c, d) analyte peptides derived from eVLP lot ‘A’. a, b Represent the y-series assignments at the 1:2 (1) and 1:32 (5) 
dilution samples respectively (see dilution scheme in Fig. 4a). Prominent y-series sequence ions are indicated. The SVG series contains 10 consecu-
tive y-series ions resulting in a MASCOT Ions Score of 69 and an Expect score of 6.7 × 10−6 at dilution ‘1’ with the ‘5’ dilution Ions Score at 57 with an 
Expect Score of 8.8 × 10−5. The SEE peptide contains 7 y-series ions in both the ‘1’ and ‘5’ dilutions with Ions Scores of 55 and 41 with Expect Scores 
of 8.2 × 10−5 and 0.0021 respectively. With the exception of the SEE ‘5’ dilution, peptide assignments from every dilution run were of sufficient qual-
ity to obtain non-ambiguous sequence identifications
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an average ΔS of 17.2  %, and the unpurified rGP mate-
rial which routinely exhibited ΔS values of 12–13  % 
(data not shown). Furthermore, we have never observed 
a higher quantitation result for GP1 from peptide Set 1 
(SEE/IRSEE) located in the middle of the molecule as 
compared to results obtained with peptide Set 2 (SVG/
SVG.R) located near the N-terminus, in any of the eVLP 
preparations. Therefore, N-terminal sequence fragments 
containing the SVG region of the protein are indeed part 
of the GP protein compliment of eVLP and the moderate 
variability shown in our data is the result of experimental 
variation only.
Targeted MS approaches, in particular selected reac-
tion monitoring (SRM) employing triple quadrupole 
mass spectrometers, have become the standard tech-
nique for quantitatively analyzing tens to hundreds of 
peptides and/or small molecules across a large number 
of samples. Unfortunately, the relatively low resolution 
of precursor m/z selection parameters can allow interfer-
ence from nominally isobaric background contaminants 
especially when interrogating complex mixtures. Addi-
tionally, because only a single parent/product ion pair is 
monitored and no mass spectra are acquired, SRM exper-
iments provide little to no qualitative information. Newer 
instrumentation platforms and configurations have facili-
tated the use of high-resolution accurate MS for quan-
titative analysis. This approach is often referred to as 
LC-HRMS and provides both qualitative and quantitative 
information during analysis by providing full-scan accu-
rate mass data for the entire chromatographic run [32, 
33]. The comprehensive detailed data obtained for each 
sample after LC-HRMS analysis was crucial for the devel-
opment of a successful quantitation strategy for Ebola 
GP1 in eVLP preparations. For example, common modi-
fications such as deamidation can often cause isotopic 
interferences, particularly when SRM-based methods are 
employed using low-resolution MS [32]. Conversely, full-
scan HRMS data allowed the unequivocal confirmation 
of deamidated endogenous target peptide species which 
improved the accuracy of our quantitation method. Fur-
thermore, high resolution MS/MS survey scans proved to 
be essential for the optimization and assessment of diges-
tion efficiency. As revealed in this work, the detailed data 
provided by LC-HRMS was essential to overcome the 
bioanalytical challenge of GP1 quantitation in eVLPs, and 
allowed us to address potential issues prior to develop-
ment of a future more streamlined quantitation scheme.
This study also highlights the superiority of mass 
spectrometry methods such as SRM and LC-HRMS for 
protein quantitation and characterization over western 
blotting and other immuno-affinity methods, which has 
been the topic of discussion in recent review articles [34, 
35]. A western blot assay depends on the specificity of a 
single antibody, and quantitative information often relies 
on a protein standard that may be poorly characterized, 
especially if evaluation is also based on reactivity to a sin-
gle antibody. This can lead to quantitative inconsistencies 
such as those which we observed in the GP1 western blot 
quantitation performed after eVLP production. How-
ever, there is definite value in validation by orthogonal 
immune-affinity approaches, and the use of the H3D5 
antibody allowed us to confirm the presence of shorter 
versions of the GP1 protein in eVLP preparations and 
unpurified recombinant GP material.
The use of crudely purified rGP material in the west-
ern blot quantitation unintentionally led to an overesti-
mation of the final GP1 concentration in eVLP, since the 
total protein concentration for the unpurified recombi-
nant GP also included GP2 as well as truncated protein 
species. Data obtained from the eVLP mouse vaccina-
tion study revealed that the amount of GP1 in each eVLP 
lot as determined by LC-HRMS, unlike the quantitative 
western blot, correlated with survival after Ebola chal-
lenge. The highest observed correlation with animal sur-
vival was obtained using the percent of GP1 in relation to 
the total protein in the VLP. This would suggest that the 
“density” of GP1 in relation to other proteins (both viral 
and host derived) present in the eVLP particle is directly 
related to the efficacy of that particular VLP preparation.
The impact of the truncated products on eVLP quality 
or suitability for vaccination has not been determined. 
However, the LC-HRMS data revealed that the eVLP lots 
Table 4 LC-HRMS results of GP1 quantitation in 5 lots of eVLP and comparison with quantitative western blot values
Lot Concentration (mg/mL) MS (CV%) Average ∆S (%) GP1 %TP
Protein rGP WB MS
A 4.7 1.0 0.55 6.0 % 15.8 11.7
B 3.3 1.14 0.33 9.9 % 7.35 8.6
C 4.8 1.4 0.29 11.6 % 12.7 6.1
D 4.9 0.7 0.15 7.2 % 24.1 3.0
E 7.2 1.1 0.09 5.2 % 25.5 1.2
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which exhibited the lowest percent survival (lots ‘D’ and 
‘E’) also contained the lowest amount of GP1 and the high-
est ΔS values (indicating an abundance of truncated GP1 
products). These truncated products may be the result of 
a frame-shift anomaly, ribosomal slippage or simply gen-
eral protein degradation. Due to the fact that the secreted 
form of GP (sGP) is produced in greater abundance 
during a natural infection than GP1,2, and since the pro-
teins share a common N-terminus, it has been speculated 
that sGP functions as a decoy molecule for EBOV-specific 
neutralizing and non-neutralizing antibodies [36]. Addi-
tionally, recent studies have shown that sGP actively sub-
verts the host immune response to induce cross-reactivity 




























































Fig. 6 Survival data in mice for quantified eVLP lots and correlation with LC-HRMS and western blot quantitation. a Average percent survival (grey 
bars) after two vaccinations in mice (n = 10 for each eVLP lot) with 10 µg of GP1 (as calculated from 6D8 western blot results) of the indicated lot. 
Vaccinations were 3 weeks apart, with 4 weeks between the final vaccination and the EBOV challenge. The percent GP1 to total protein concen-
tration (right axis) obtained using LC-HRMS is represented by the white bars. Survival in all vaccinated groups was significant (p < 0.005) when 
compared to saline controls. Fisher’s Exact test was used to compare survival between the group vaccinated with eVLP lot ‘E’ and the other lots 
(*indicates p < 0.01, **indicates p < 0.001). b LC-HRMS and western blot values for GP1 content in each eVLP lot tested (based on % total protein 
or mg/mL) were plotted against percent survival in mice after EBOV challenge (note: since Lots A and B both gave 100 % the lower lot B value was 
used resulting in a total of 4 data points). The strongest linear correlation (R2 = 0.936) was obtained with the LC-HRMS GP1 values based on % total 
protein followed by the LC-HRMS values for GP1 in mg/mL (R
2 = 0.9096)
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Therefore, truncated versions of the GP1 protein may 
indeed compromise the quality and effectiveness of eVLP 
vaccines, and lots exhibiting a high level of these frag-
ments should not be used for vaccination studies.
Conclusions
A LC-HRMS approach resulted in the successful quan-
titation of GP1 in eVLP vaccine preparations. The use 
of this newly developed assay will allow us to monitor 
variability based on GP1 content, providing quality con-
trol information to further optimize and refine the eVLP 
production process for vaccine studies. Finally, using 
this quantitative LC-HRMS approach, the total amount 
of GP1 necessary to confer protection can be accu-
rately determined; a crucial factor in successful vaccine 
development.
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